Felzartamab plus lenalidomide-dexamethasone versus lenalidomide-dexamethasone for relapsed or refractory multiple myeloma: an open-label, parallel-controlled, randomised, phase 3 trial.
Adding felzartamab to standard treatment significantly extended progression-free survival in patients with relapsed or refractory multiple myeloma.
This randomized controlled trial examined Felzartamab plus lenalidomide-dexamethasone versus lenalidomide-dexamethasone for relapsed or refractory multiple myeloma: an open-label, parallel-controlled, randomised, phase 3 trial. INTERPRETATION: Felzartamab plus lenalidomide-dexamethasone significantly prolonged progression-free survival compared with lenalidomide-dexamethasone alone, supporting felzartamab plus lenalidomide-dexamethasone as a potential new treatment option for Chinese patients with relapsed or refractory multiple myeloma.
What the study was
- Study design
- Randomized controlled trial
- Population
- Human participants or patients described in the PubMed abstract
- Sample size
- 195
- Category
- Other
- Maturity
- Validated
- Journal
- The Lancet. Haematology
Why it surfaced
Randomized controlled trial; conservative rapid-triage score based on novelty, clinical relevance, design quality, and population or unmet need.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.